1 Min Read
Aug 13 (Reuters) - Genentech Inc:
* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR XOLAIR (OMALIZUMAB) FOR FOOD ALLERGIES Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.